317 related articles for article (PubMed ID: 24571780)
1. Pharmacologic therapy for diabetic retinopathy.
Gardlik R; Fusekova I
Semin Ophthalmol; 2015 Jul; 30(4):252-63. PubMed ID: 24571780
[TBL] [Abstract][Full Text] [Related]
2. Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy.
Simó R; Sundstrom JM; Antonetti DA
Diabetes Care; 2014 Apr; 37(4):893-9. PubMed ID: 24652720
[TBL] [Abstract][Full Text] [Related]
3. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Ajlan RS; Silva PS; Sun JK
Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
[TBL] [Abstract][Full Text] [Related]
4. Current trends in the pharmacotherapy of diabetic retinopathy.
Kumar B; Gupta SK; Saxena R; Srivastava S
J Postgrad Med; 2012; 58(2):132-9. PubMed ID: 22718058
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic targets in diabetic macular edema: Beyond VEGF.
Urias EA; Urias GA; Monickaraj F; McGuire P; Das A
Vision Res; 2017 Oct; 139():221-227. PubMed ID: 28993218
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenesis drugs in diabetic retinopathy.
Jeganathan VS
Curr Pharm Biotechnol; 2011 Mar; 12(3):369-72. PubMed ID: 20939797
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGF Therapy for Diabetic Eye Diseases.
Bahrami B; Hong T; Gilles MC; Chang A
Asia Pac J Ophthalmol (Phila); 2017; 6(6):535-545. PubMed ID: 29076303
[TBL] [Abstract][Full Text] [Related]
8. Review of anti-VEGF therapy in proliferative diabetic retinopathy.
Jardeleza MS; Miller JW
Semin Ophthalmol; 2009; 24(2):87-92. PubMed ID: 19373692
[TBL] [Abstract][Full Text] [Related]
9. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema.
Matsuda S; Tam T; Singh RP; Kaiser PK; Petkovsek D; Carneiro G; Zanella MT; Ehlers JP
J Diabetes Complications; 2014; 28(2):166-70. PubMed ID: 24374138
[TBL] [Abstract][Full Text] [Related]
10. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications.
Cheung N; Wong IY; Wong TY
Diabetes Care; 2014 Apr; 37(4):900-5. PubMed ID: 24652721
[TBL] [Abstract][Full Text] [Related]
11. Improvement of diabetic retinopathy with intravitreal Ranibizumab.
Kernt M; Cserhati S; Seidensticker F; Liegl R; Kampik A; Neubauer A; Ulbig MW; Reznicek L
Diabetes Res Clin Pract; 2013 Apr; 100(1):e11-3. PubMed ID: 23391744
[TBL] [Abstract][Full Text] [Related]
12. What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?
Agarwal A; Sarwar S; Sepah YJ; Nguyen QD
Curr Opin Ophthalmol; 2015 May; 26(3):177-83. PubMed ID: 25784111
[TBL] [Abstract][Full Text] [Related]
13. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for diabetic retinopathy.
Pipis A; Scholl S; Augustin AJ
Expert Opin Emerg Drugs; 2011 Dec; 16(4):669-81. PubMed ID: 22112046
[TBL] [Abstract][Full Text] [Related]
15. Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?
Das A; McGuire PG; Monickaraj F
Indian J Ophthalmol; 2016 Jan; 64(1):4-13. PubMed ID: 26953018
[TBL] [Abstract][Full Text] [Related]
16. [Anti-VEGF therapy for diabetic retinopathy].
Chekhonin ES; Fayzrakhmanov RR; Sukhanova AV; Bosov ED
Vestn Oftalmol; 2021; 137(4):136-142. PubMed ID: 34410069
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
18. Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review.
Zehden JA; Mortensen XM; Reddy A; Zhang AY
Curr Diab Rep; 2022 Oct; 22(10):525-536. PubMed ID: 36053385
[TBL] [Abstract][Full Text] [Related]
19. [Anti-VEGF: one drug for different conditions?].
Cohen SY; Massin P; Souied E
J Fr Ophtalmol; 2013 Jan; 36(1):2-4. PubMed ID: 23290491
[No Abstract] [Full Text] [Related]
20. Pharmacological approach to diabetic macular edema.
Bandello F; Casalino G; Loewenstein A; Goldstein M; Pelayes D; Battaglia Parodi M
Ophthalmic Res; 2014; 51(2):88-95. PubMed ID: 24356667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
